Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI)
Listed as NCT00608972, this PHASE2 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Rutgers Cancer Institute of New Jersey
- Rutgers, The State University of New Jersey
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Camden, United States
- • Hamilton, United States
- • Morristown, United States
- • Neptune City, United States
- • New Brunswick, United States
- • Summit, United States